"Alphabet's Isomorphic Secures Drug Discovery Deals with Eli Lilly and Novartis Worth $2.98B"

Isomorphic Labs, an AI startup under Alphabet, has announced partnerships with pharmaceutical giants Eli Lilly and Novartis in deals potentially worth up to $3 billion. The company, led by CEO Demis Hassabis, aims to leverage AI technology from Google DeepMind, such as the AlphaFold model, to accelerate drug discovery. Isomorphic Labs has been rapidly growing in the AI biotech sector since its inception in November 2021 and currently has a significant presence in London and Lausanne.